Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Prasad Palani Velu (Edinburgh, United Kingdom), Prasad Palani Velu, Pallavi Bedi, Kim Turnbull, Adam T. Hill. Longitudinal performance of the bronchiectasis severity index (BSI) in patients on regular intravenous (IV) antibiotic therapy for bronchiectasis. Eur Respir J 2016; 48: Suppl. 60, 2554

Member's Comments

No comment yet.

Related content which might interest you: Influence of severity on outcome in a phase II trial of ciprofloxacin DPI in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients Year: 2013 The prevalence and characteristics of intravenous (IV) antibiotics allergy in adult patient with cystic fibrosis (CF) Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems Year: 2012 Scond may better discriminate severe therapy resistant asthma (STRA) from mild-moderate asthma than lung clearance index (LCI) Source: International Congress 2016 – Advanced lung function testing in childhood respiratory and sleep disease Year: 2016 Antibiotic treatment strategies in adults with bronchiectasis Source: Eur Respir Mon 2011; 52: 211-222 Year: 2011 Ventilation inhomogeneity (VI) and spirometry in response to intravenous antibiotics (IVab) in cystic fibrosis (CF) Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 Pulmonary targeted antibiotics in bronchiectasis; inhalers vs. nebulisers. A qualitative and quantitative assessment of patients’ attitudes Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF) Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Nebulised antibiotics with the I-neb adaptive aerosol delivery (AAD) system: Impact on adherence in cystic fibrosis (CF) patients Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems Year: 2012 Quantitative analysis of severe asthma exacerbation requiring continuous inhalation therapy by measurements of modified pulmonary index score Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Clinical characteristics, pulmonary function, and response to beta2-agonist: Patients with asthma vs. patients with asthma/COPD overlap syndrome Source: Annual Congress 2013 –Asthma at the bedside Year: 2013 Treatment effect of inhaled prolonged bronchodilator therapy (IPBT) combined with inhaled glucocorticosteroids (IGCS) on respiratory symptoms and external respiratory function in MDR pulmonary TB patients with broncho-obstructive syndrome (BOS) Source: Annual Congress 2012 - New insights in the clinical management of lung diseases Year: 2012 A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Change in lung clearance index (LCI) following intravenous antibiotic intervention in children with CF Source: Annual Congress 2008 - Respiratory physiology in health and disease Year: 2008 Rheumatoid arthritis and bronchiectasis: A multicentre study assessing pulmonary disease severity using the bronchiectasis severity index (BSI) Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014 Efficacy of using special software “Optimization of medication choice for treatment of patient with comorbidity” (SS) for management of patients with community-acquired pneumonia (CAP) and cardiovascular disease Source: International Congress 2019 – M-health/e-health I Year: 2019 Risk of pneumonia in chronic obstructive pulmonary disease patients treated with inhaled corticosteroids. Results from the OUTPUL study Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 Patients’ adherence to chronic treatment of pulmonary diseases Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013